Regado Biosciences files for a $75 million IPO

By Renaissance Capital,

Shutterstock photo

Regado Biosciences, which is focused on the discovery and development of drugs for cardiovascular indications, filed on Monday with the SEC to raise up to $75 million in an initial public offering. The company is backed by founder of Fastenal and former Minnesota Senator, Robert Kierlin, who holds a 27% stake.

The Basking Ridge, NJ-based company, which was founded in 2001 and booked no revenue for the 2012 fiscal year, plans to list on the NASDAQ under the symbol RGDO. Regado Biosciences initially filed confidentially on 3/1/2013. Cowen & Company and BMO Capital Markets are the joint bookrunners on the deal. No pricing terms were disclosed.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

This article appears in: News Headlines IPOs
Referenced Stocks: RGDO

More from Renaissance Capital


Renaissance Capital

Renaissance Capital

Follow on:

Find a Credit Card

Select a credit card product by:
Select an offer:
Data Provided by